Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07084467

A Study Testing a New Heart Scan Method to Improve Pacemaker Treatment for Heart Failure

Evaluation of First-Phase Ejection Fraction to Guide Cardiac Resynchronization Therapy - A Randomised Controlled Trial

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
400 (estimated)
Sponsor
King's College London · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Cardiac resynchronization therapy (CRT) is a device treatment for patients with heart failure which cannot be managed by medications alone. CRT can help the heart contract more efficiently and improve the pumping function. However, many patients do not benefit from this treatment. Therefore, a better selection tool will help us to determine the most suitable patients to receive this treatment. A new measure of pumping function of the heart called: first-phase ejection fraction or EF1 has been shown a good tool to select suitable patients for CRT. EF1 is a sensitive measurement of heart function and can be easily measured by echocardiography (an ultrasound heart scan). The purpose of this study is to examine whether this new measurement (EF1) can predict outcomes and response to CRT treatment.

Conditions

Interventions

TypeNameDescription
OTHEREF1 guided CRT optimisationIn the EF1-guided optimisation group, the settings of the CRT device are adjusted to maximise early heart pumping efficiency, measured by a parameter called first-phase ejection fraction (EF1). Depending on the patient's heart rhythm, either the timing between heart chambers (AV or VV delay) is adjusted in small steps. The device setting that gives the best EF1 reading is chosen to help improve the heart's response to CRT.
OTHERStandard of Care (SOC)This group will receive standard of care for their health condition and CRT management.

Timeline

Start date
2025-08-01
Primary completion
2030-07-31
Completion
2030-07-31
First posted
2025-07-24
Last updated
2025-08-03

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT07084467. Inclusion in this directory is not an endorsement.